Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Cue Biopharma, Inc. (NASDAQ: CUE).

Full DD Report for CUE

You must become a subscriber to view this report.


Recent News from (NASDAQ: CUE)

Cue Biopharma Announces Presentation at the Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting
CAMBRIDGE, Mass., Oct. 30, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma ™, Inc., (NASDAQ: CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic infect...
Source: GlobeNewswire
Date: October, 30 2018 08:00
Cue Biopharma, Inc. (CUE) CEO Dan Passeri Hosts Investor Business Update Call (Transcript)
Cue Biopharma, Inc. (CUE) Investor Business Update Call August 23, 2018 08:30 AM ET Executives John Woolford - Westwicke Partners Dan Passeri - President and CEO Anish Suri - Chief Scientific Officer Bethany Mancilla - Chief Business Officer Kerri-Ann Millar - VP of Finan...
Source: SeekingAlpha
Date: August, 27 2018 19:14
Cue Biopharma (CUE) Investor And Analyst Update - Slideshow
The following slide deck was published by Cue Biopharma in conjunction with this Read more ...
Source: SeekingAlpha
Date: August, 24 2018 13:39
Cue Biopharma Adds Frank Morich, M.D., Ph.D. to Board of Directors
CAMBRIDGE, Mass., Aug. 03, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma , Inc., (NASDAQ:CUE) a next-generation immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic infectious di...
Source: GlobeNewswire
Date: August, 03 2018 08:00
Cue Biopharma Appoints Bethany Mancilla as Chief Business Officer and Senior Vice President
CAMBRIDGE, Mass., July 24, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma , Inc., (NASDAQ:CUE) a next-generation immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic infectious di...
Source: GlobeNewswire
Date: July, 24 2018 08:00
Cue Biopharma Produces Immuno-STAT(TM) Biologic Candidate for Treatment of Autoimmune Disease Under Collaboration and License Agreement with Merck
CAMBRIDGE, Mass., July 12, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma , Inc., an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer and autoimmune diseases, today announced progress in its ongoing ...
Source: GlobeNewswire
Date: July, 12 2018 08:00
Stocks To Watch: Tariffs Don't Take Holidays
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. As usual, a new quarter and the second half of the trading year will begin with a sh...
Source: SeekingAlpha
Date: June, 30 2018 09:08
Cue Biopharma Strengthens Board of Directors with Addition of Fred Driscoll to Chair Audit Committee
CAMBRIDGE, Mass., June 28, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma , Inc., (NASDAQ:CUE) a next-generation immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer and autoimmune diseases, announced to...
Source: GlobeNewswire
Date: June, 28 2018 09:15
Cue Biopharma to Host Investor Business Update Call and Webcast
CAMBRIDGE, Mass., May 10, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma , Inc. (NASDAQ:CUE), an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer and autoimmune diseases, announced today t...
Source: GlobeNewswire
Date: May, 10 2018 08:00
Cue Biopharma Announces Appointment of Anish Suri, Ph.D. as Chief Scientific Officer
CAMBRIDGE, Mass., April 25, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma , Inc. (NASDAQ:CUE), an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancer and autoimmune diseases...
Source: GlobeNewswire
Date: April, 25 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-089.189.249.298.8824,681
2018-05-1714.3314.2014.7514.17125,498

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-185,67714,68938.6480Short
2018-12-1724,38937,70064.6923Short
2018-12-147,42316,08846.1400Short
2018-12-135,1918,20163.2972Short
2018-12-123,3869,04137.4516Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CUE.


About Cue Biopharma, Inc. (NASDAQ: CUE)

Logo for Cue Biopharma, Inc. (NASDAQ: CUE)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: CUE)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 17 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 14 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 30 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 30 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 30 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 29 2018
      Securities offered to employees under employee benefit plans
      Filing Type: S-8Filing Source: edgar
      Filing Date: March, 29 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: February, 13 2018
      Amendment to a previously filed Form 3
      Filing Type: 3/AFiling Source: edgar
      Filing Date: February, 13 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: January, 26 2018

       

       


      Daily Technical Chart for (NASDAQ: CUE)

      Daily Technical Chart for (NASDAQ: CUE)


      Stay tuned for daily updates and more on (NASDAQ: CUE)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: CUE)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CUE is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of CUE and does not buy, sell, or trade any shares of CUE. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/